According to filings with the U.S. Securities and Exchange Commission, Ambient Biosciences is raising up to $5,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Ambient Biosciences
At Ambient Biosciences, we are dedicated to being a true partner in your success. We bring the same spirit of versatility, transparency, and innovation to our customer relationships as we do to our technology. Our approach is to take the mystery out of biomolecule stabilization, making it an accessible and collaborative process that empowers you to feel confident about your products and assays.

To learn more about Ambient Biosciences, visit http://www.ambientbio.com/
Ambient Biosciences Linkedin Page: https://www.linkedin.com/company/ambientbiosciences/

Contact:
Richard Troyer, Chief Executive Officer
734-215-5345
https://www.linkedin.com/in/richardtroyer1993/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.